>> So there must be [Tarceva] benefit over and above the 10% or so with the particular egf mutations and over and above what's seen with iressa. <<
The first half of your statement is tautological given the definition of median survival, so it requires no discussion.
If I am interpreting you correctly, the second half of your statement seems to imply that Tarceva is a better drug than Iressa. This strikes me as a leap of faith since there are no head-to-head data and median survival was not measured in the Iressa trials in refractory NSCLC.
Market Data 
Markets 
AI
